122 related articles for article (PubMed ID: 19680167)
1. Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone.
Ogata S; Ogihara Y; Nomoto K; Akiyama K; Nakahata Y; Sato K; Minoura K; Kokubo K; Kobayashi H; Ishii M
Pediatr Res; 2009 Nov; 66(5):577-84. PubMed ID: 19680167
[TBL] [Abstract][Full Text] [Related]
2. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
Ogata S; Ogihara Y; Honda T; Kon S; Akiyama K; Ishii M
Pediatrics; 2012 Jan; 129(1):e17-23. PubMed ID: 22144699
[TBL] [Abstract][Full Text] [Related]
4. [Steroid pulse therapy].
Miura M
Nihon Rinsho; 2014 Sep; 72(9):1631-5. PubMed ID: 25518414
[TBL] [Abstract][Full Text] [Related]
5. [Methylprednisolone pulse therapy in Kawasaki disease].
Miura M; Matsuoka M; Kohno K; Ohki H; Yoshiba S
Nihon Rinsho; 2008 Feb; 66(2):338-42. PubMed ID: 18265457
[TBL] [Abstract][Full Text] [Related]
6. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
[TBL] [Abstract][Full Text] [Related]
7. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.
Fury W; Tremoulet AH; Watson VE; Best BM; Shimizu C; Hamilton J; Kanegaye JT; Wei Y; Kao C; Mellis S; Lin C; Burns JC
Hum Immunol; 2010 Sep; 71(9):865-73. PubMed ID: 20600450
[TBL] [Abstract][Full Text] [Related]
8. Response of refractory Kawasaki disease to intravenous methylprednisolone.
Shah I; Prabhu SS
Ann Trop Paediatr; 2009 Mar; 29(1):51-3. PubMed ID: 19222935
[TBL] [Abstract][Full Text] [Related]
9. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin.
Miura M; Kohno K; Ohki H; Yoshiba S; Sugaya A; Satoh M
Eur J Pediatr; 2008 Oct; 167(10):1119-23. PubMed ID: 18175148
[TBL] [Abstract][Full Text] [Related]
10. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
Hashino K; Ishii M; Iemura M; Akagi T; Kato H
Pediatr Int; 2001 Jun; 43(3):211-7. PubMed ID: 11380911
[TBL] [Abstract][Full Text] [Related]
11. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.
Loomba RS; Raskin A; Gudausky TM; Kirkpatrick E
Am J Ther; 2016; 23(6):e1293-e1299. PubMed ID: 25611359
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
Sundel RP; Baker AL; Fulton DR; Newburger JW
J Pediatr; 2003 Jun; 142(6):611-6. PubMed ID: 12838187
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
Ogihara Y; Ogata S; Nomoto K; Ebato T; Sato K; Kokubo K; Kobayashi H; Ishii M
Pediatr Res; 2014 Sep; 76(3):287-93. PubMed ID: 24964229
[TBL] [Abstract][Full Text] [Related]
14. Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease.
Kanamitsu K; Kakimoto H; Shimada A; Nakata Y; Ochi H; Watanabe H; Iwasaki Y; Tokorodani C; Kanazawa A; Maruyama H; Miyazawa M; Nishiuchi R; Kikkawa K
Pediatr Int; 2016 Feb; 58(2):146-51. PubMed ID: 26190225
[TBL] [Abstract][Full Text] [Related]
15. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
Crayne CB; Mitchell C; Beukelman T
Pediatr Rheumatol Online J; 2019 Nov; 17(1):77. PubMed ID: 31775898
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
Chen S; Dong Y; Yin Y; Krucoff MW
Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
[TBL] [Abstract][Full Text] [Related]
18. Monocyte-Derived Interleukin-1β As the Driver of S100A12-Induced Sterile Inflammatory Activation of Human Coronary Artery Endothelial Cells: Implications for the Pathogenesis of Kawasaki Disease.
Armaroli G; Verweyen E; Pretzer C; Kessel K; Hirono K; Ichida F; Okabe M; Cabral DA; Foell D; Brown KL; Kessel C
Arthritis Rheumatol; 2019 May; 71(5):792-804. PubMed ID: 30447136
[TBL] [Abstract][Full Text] [Related]
19. Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.
Inoue T; Murakami S; Matsumoto K; Matsuda A
Pediatr Rheumatol Online J; 2020 Oct; 18(1):76. PubMed ID: 33023630
[TBL] [Abstract][Full Text] [Related]
20. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
Youn Y; Kim J; Hong YM; Sohn S
Pediatr Infect Dis J; 2016 Apr; 35(4):457-9. PubMed ID: 26673981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
